MLICM
KALV

Metropolitan Life Insurance Company (MetLife)’s KalVista Pharmaceuticals KALV Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,820
Closed -$21.6K – 1102
2024
Q1 		$21.6K Hold
1,820
– – ﹤0.01% 1818
2023
Q4 		$22.3K Buy
1,820
+467
+35% +$4.25K ﹤0.01% 1872
2023
Q3 		$13K Hold
1,353
– – ﹤0.01% 2094
2023
Q2 		$12.2K Hold
1,353
– – ﹤0.01% 2195
2023
Q1 		$10.6K Sell
1,353
-182
-12% -$1.36K ﹤0.01% 2134
2022
Q4 		$10.4K Buy
1,535
+161
+12% +$862 ﹤0.01% 2273
2022
Q3 		$19.9K Hold
1,374
– – ﹤0.01% 2030
2022
Q2 		$13.5K Hold
1,374
– – ﹤0.01% 2230
2022
Q1 		$20.3K Sell
1,374
-3,900
-74% -$56K ﹤0.01% 2089
2021
Q4 		$69.8K Hold
5,274
– – ﹤0.01% 2641
2021
Q3 		$92K Buy
5,274
+236
+5% +$4.78K ﹤0.01% 2568
2021
Q2 		$121K Hold
5,038
– – ﹤0.01% 2499
2021
Q1 		$129K Buy
5,038
+104
+2% +$2.73K ﹤0.01% 2306
2020
Q4 		$93.7K Buy
+4,934
New +$84.6K ﹤0.01% 2386
2019
Q3 		– Sell
-992
Closed -$22K – 2597
2019
Q2 		$22K Buy
+992
New +$23.3K ﹤0.01% 2594

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s KALV Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of KalVista Pharmaceuticals (KALV) in Q2 2024, closing a stake of 1,820 shares — an estimated $21.6K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in KALV in Q2 2019 and held it in 15 quarters. The position peaked at $129K in Q1 2021. 119 funds tracked by Wall St. Rank hold KALV as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining KalVista Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,820 KalVista Pharmaceuticals shares in Q2 2024, an estimated $21.6K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in KalVista Pharmaceuticals in Q2 2019 and held it in 15 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s KalVista Pharmaceuticals position peaked at $129K in Q1 2021.
  • 119 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.